Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Katherine P. Hearn, BSN, RN, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, CCRN, Yesid Alvarado, MD, Naval Daver, MD, Courtney D DiNardo, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Pierre Fenaux, MD PhD, Michael E. Petrone, MD MPH, Patrick Simon Zbyszewski, MBA, Steven M. Fruchtman, MD, Lewis R. Silverman, MD

Blood (2016) 128 (22): 3167.

https://doi.org/10.1182/blood.V128.22.3167.3167

Published: 2016

Journal Articles

A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)

Shyamala C. Navada, MD, Lewis R. Silverman, MD, Katherine P. Hearn, BSN, RN, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, CCRN, Yesid Alvarado, MD, Naval Daver, MD, Courtney DiNardo, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Tapan Kadia, MD, Pierre Fenaux, MD PhD, Steve Fruchtman, MD, Nozar Azarnia, PhD, Guillermo Garcia-Manero, MD

Blood (2015) 126 (23): 910.

https://doi.org/10.1182/blood.V126.23.910.910

Published: 2015

Journal Articles

Intravenous Immunoglobulin Is an Effective Treatment for LGL-Mediated Immune Cytopenias in Myelodysplastic Syndromes and Other Bone Marrow Failure Syndromes

Francesca Schieppati, Erin P. Demakos, RN, CCRN, Odchimar Rosalie-Reissig, RN, Shyamala C. Navada, MD, Lewis R. Silverman, MD

Blood (2015) 126 (23): 1704.

https://doi.org/10.1182/blood.V126.23.1704.1704

Published: 2015

Journal Articles

Incidence and Treatment of Myelodysplastic Syndrome in the US: Treatment Approaches, Optimization of Care and the Need for Additional Therapeutic Agents

Erin P. Demakos, RN, CCRN, Lewis R. Silverman, MD, Moira E. Lawrence, PhD, Thomas J. McKearn, MD PhD, Scott Megaffin, Rita Percy, Michael E. Petrone, MD MPH

Blood (2014) 124 (21): 1287.

https://doi.org/10.1182/blood.V124.21.1287.1287

Published: 2014

Journal Articles

A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Francois Wilhelm, MD PhD, Katherine Hearn, RN, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, CCRN, Yesid Alvarado, MD, Naval Daver, MD, Courtney D. DiNardo, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Nozar Azarnia, PhD, Lewis R. Silverman, MD

Blood (2014) 124 (21): 3252.

https://doi.org/10.1182/blood.V124.21.3252.3252

Published: 2014

Journal Articles

Predictors Of Response To Rigosertib In Patients With a Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) Relapsing After Or Refractory To Hypomethylating Agents

Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, E. Premkumar Reddy, PhD, Erin P Demakos, RN, CCRN, James F Holland, MD, Francois Wilhelm, MD, PhD., Lewis R. Silverman, MD

Blood (2013) 122 (21): 1527.

https://doi.org/10.1182/blood.V122.21.1527.1527

Published: 2013

Journal Articles

Dose Escalation of Azacitidine in Patients Failing Standard or Investigational Combinations of the Agent in the Myelodysplastiic Syndrome or Evolved AML

Lewis R. Silverman, MD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Maria Michalak, PA-C, Erin P Demakos, RN, CCRN, James F Holland, MD

Blood (2012) 120 (21): 4932.

https://doi.org/10.1182/blood.V120.21.4932.4932

Published: 2012

NARROW

Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study

A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)

Intravenous Immunoglobulin Is an Effective Treatment for LGL-Mediated Immune Cytopenias in Myelodysplastic Syndromes and Other Bone Marrow Failure Syndromes

Incidence and Treatment of Myelodysplastic Syndrome in the US: Treatment Approaches, Optimization of Care and the Need for Additional Therapeutic Agents

A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)

Predictors Of Response To Rigosertib In Patients With a Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) Relapsing After Or Refractory To Hypomethylating Agents

Dose Escalation of Azacitidine in Patients Failing Standard or Investigational Combinations of the Agent in the Myelodysplastiic Syndrome or Evolved AML

Email alerts

ASH Publications

American Society of Hematology

Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study

A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)

Intravenous Immunoglobulin Is an Effective Treatment for LGL-Mediated Immune Cytopenias in Myelodysplastic Syndromes and Other Bone Marrow Failure Syndromes

Incidence and Treatment of Myelodysplastic Syndrome in the US: Treatment Approaches, Optimization of Care and the Need for Additional Therapeutic Agents

A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)

Predictors Of Response To Rigosertib In Patients With a Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) Relapsing After Or Refractory To Hypomethylating Agents

Dose Escalation of Azacitidine in Patients Failing Standard or Investigational Combinations of the Agent in the Myelodysplastiic Syndrome or Evolved AML

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only